October 13, 2023 - InterVenn Biosciences Announces the Publication of Early Detection of Advanced Adenoma and Colorectal Cancer in Gastroenterology, the Flagship Journal of the American Gastroenterological Association
Read more
September 27, 2023 - InterVenn Biosciences Welcomes Accomplished Diagnostics Executive Joshua Stahl as CEO
Read more
May 8, 2023 - InterVenn Demonstrates Power of Its GlycoVision™ Platform In Advanced Adenoma and Colorectal Cancer
Read more
April 19, 2023 - InterVenn Biosciences to Present Clinical Data on Circulating Serum Glycoproteins for Unprecedented Pre-Cancer Detection as “Poster of Distinction” at Digestive Disease Week 2023
Read more
January 5, 2023 - InterVenn Biosciences Enters Next Stage with Senior Management Team Updates Focused on Commercialization
Read more
January 3, 2023 - InterVenn Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023
Read more
November 10, 2022 - InterVenn Biosciences to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
Read more
October 26, 2022 - Erwin Estigarribia is Appointed President and Chief Operating Officer of InterVenn Biosciences
Read more
October 6, 2022 - InterVenn Biosciences Co-Founder Carolyn Bertozzi Awarded Nobel Prize in Chemistry
Read more
October 4, 2022 - InterVenn Biosciences Expands Board of Directors with Dr. Jason Myers and Carol Berry to Support Next Phase of Growth
Read more
August 2, 2022 - InterVenn Biosciences Announces Start of Enrollment in Colonoscopy Study
Read more
July 21, 2022 - InterVenn Expands Global Presence to Drive the Potential of Glycoproteomics to Improve Patient Outcomes
Read more
June 2, 2022 - InterVenn Biosciences Announces New Data Validating the Clinical Performance of DAWN™ IO Melanoma as a Novel Liquid Biopsy Test to Improve Assessment of Benefit to Cancer Patients
Read more
June 1, 2022 - InterVenn Biosciences Joins the WIN and FNIH Biomarker Consortiums to Introduce a Glycoproteomic Option for Liquid Biopsies
Read more
May 6, 2022 - InterVenn to Present New Clinical Data at ASCO 2022 on Using Glycoproteomics as Powerful Liquid Biopsy Tests for Early Detection of Cancer and Prediction of Checkpoint Inhibitor Treatment Benefit
Read more
January 5, 2022 - InterVenn Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022
Read more
2 Tower Place, 5th Floor,
South San Francisco, CA 94080
Bay Area Lab
